Mon. 18 Mar 2024, 2:24am ET
Benzinga
News
- Subgroup experienced efficacy and safety consistent with overall study population
- Advanced malignant PEComa tumors of gynecologic origin accounted for more than half of the evaluable patients enrolled in AMPECT
- Additional data presented highlight nab-sirolimus as potential approach for mTOR-driven gynecologic cancers